Citation 1:
    Title: Amgen Inc Stock Price Forecast 2025, 2026, 2030 to 2050
    URL: https://stockscan.io/stocks/AMGN/forecast
    Location: 

Citation 2:
    Title: 8-K: AMGEN REPORTS SECOND QUARTER 2025 ...
    URL: https://news.moomoo.com/notice/305166753/amgen-8-k-amgen-reports-second-quarter-2025-financial-results
    Location: 

Citation 3:
    Title: Forecasting The Future: 7 Analyst Projections For Amgen
    URL: https://www.nasdaq.com/articles/forecasting-future-7-analyst-projections-amgen
    Location: 

Citation 4:
    Title: AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL ...
    URL: https://www.prnewswire.com/news-releases/amgen-reports-first-quarter-2025-financial-results-302444435.html
    Location: 

Citation 5:
    Title: Will Amgen (AMGN) stock be able to reach new record ...
    URL: https://www.economies.com/stocks/united-states-analysis/will-amgen-(amgn)-stock-be-able-to-reach-new-record-levels-before-the-end-of-2024%20-113155
    Location: 

Citation 6:
    Title: Amgen | 10-Q: Q2 2025 Earnings Report
    URL: https://news.moomoo.com/notice/305175886/amgen-10-q-q2-2025-earnings-report
    Location: 

Citation 7:
    Title: AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 ...
    URL: https://www.nasdaq.com/articles/amgns-key-drugs-repatha-evenity-blincyto-drive-q1-sales-growth
    Location: 

Citation 8:
    Title: AMGEN REPORTS FOURTH QUARTER AND FULL YEAR ...
    URL: https://www.amgen.com/newsroom/press-releases/2025/02/amgen-reports-fourth-quarter-and-full-year-2024-financial-results
    Location: 

Citation 9:
    Title: AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 ...
    URL: https://www.prnewswire.com/news-releases/amgen-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth-factor-receptor-2b-fgfr2b-positive-first-line-gastric-cancer-302494006.html
    Location: 

Citation 10:
    Title: Inside Amgen's Phase 3 MARITIME Program
    URL: https://www.amgen.com/stories/2025/06/inside-amgens-phase-3-maritime-program---advancing-the-future-of-obesity-care
    Location: 

Citation 11:
    Title: As patent cliffs loom, Morgan Stanley predicts M&A surge
    URL: https://www.fiercepharma.com/pharma/firepower-aplenty-and-patent-cliffs-ahead-time-right-ma-activity-report
    Location: 

Citation 12:
    Title: UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST ...
    URL: https://www.amgen.com/newsroom/press-releases/2025/04/uplizna-inebilizumabcdon-is-now-the-first-and-only-fdaapproved-treatment-for-igg4related-disease
    Location: 

Citation 13:
    Title: Amgen's late-stage obesity trials are expected to readout ...
    URL: https://www.fiercebiotech.com/biotech/amgen-enters-maritime-launching-2-late-stage-obesity-trials-maritide
    Location: 

Citation 14:
    Title: Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive ...
    URL: https://www.nasdaq.com/articles/amgens-q1-earnings-beat-estimates-key-drugs-drive-sales-growth
    Location: 

Citation 15:
    Title: Amgen (AMGN) Balance Sheet & Financial Health Metrics
    URL: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/health
    Location: 

Citation 16:
    Title: Amgen settles Prolia patent suit with Celltrion, teeing up ...
    URL: https://www.fiercepharma.com/pharma/after-sandoz-amgen-settles-patent-suit-celltrion-postponing-potential-launch-prolia-xgeva
    Location: 

Citation 17:
    Title: With patent losses on the horizon, Amgen refocuses its ...
    URL: https://www.pharmavoice.com/news/amgen-patent-loss-business-strategy-otezla-enbrel-biosimilars/741572/
    Location: 

Citation 18:
    Title: Amgen's Stelara biosimilar gets off to fast start
    URL: https://www.biopharmadive.com/news/amgen-stelara-biosimilar-sales-first-quarter-earnings/746982/
    Location: 

Citation 19:
    Title: AMGN Forecast — Price Target — Prediction for 2026
    URL: https://www.tradingview.com/symbols/NASDAQ-AMGN/forecast/
    Location: 

Citation 20:
    Title: Amgen Inc. (NASDAQ:AMGN) is a favorite amongst ...
    URL: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-inc-nasdaqamgn-is-a-favorite-amongst-institutional-inv-1
    Location: 

Citation 21:
    Title: $2580000 of AMGEN INC lobbying was just disclosed
    URL: https://www.quiverquant.com/news/Lobbying+Update:+$2,580,000+of+AMGEN+INC+lobbying+was+just+disclosed
    Location: 

